Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $350
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $330 to $350.
June 12, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Biogen and raises the price target from $330 to $350.
The raised price target by Canaccord Genuity indicates a positive outlook for Biogen's stock. This news is directly related to BIIB and is important for investors as it suggests potential upside in the stock price. The confidence in the analysis is high due to the credibility of Canaccord Genuity as a financial analyst firm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100